EZ4U – Cell Proliferation & Cytotoxicity Assay

Widely cited non-radioactive EZ4U – Cell Proliferation & Cytotoxicity Assay – single step incubation for use on living cells

The Biomedica EZ4U cell proliferation and cytotoxicity assay  was highlighted in a recent study investigating the cytotoxicity of drug combinations tested against different pancreatic cell lines.  Learn more: Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines.

Pancreatic ductal adenocarcinomas (PDACs), the most prevalent pancreatic cancer, is highly aggressive with a 5-year overall survival rate of less than 8%.  Late detection, it´s metastatic spread and the resistance to chemotherapy are among some of the factors responsible for poor patient outcome. The PDAC incidence rate is increasing and is particularly related to the general aging of our society. Furthermore, life style habits that include abuse of alcohol and tobacco as well as obesity and type 2 diabetes increases the risk for various types of cancer including PDAC.

EZ4U – Cell Proliferation & Cytotoxicity Assay (cat.no. BI-5000)

-Non-radioactive & non-toxic assay

-Reliable & Sensitive

-Convenient single-step incubation  – for use on living cells

-Widely cited in more than 230 publications

BROCHURE – EZ4U cell proliferation and cytotoxicity assay

 

FURTHER READING

Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy.

World J Gastrointest Oncol. Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. 2020 Feb 15;12(2):173-181. doi: 10.4251/wjgo.v12.i2.173. PMID: 32104548; PMCID: PMC7031151.

 

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases, with an average 5-year survival rate of less than 10%. Unfortunately, the majority of patients have unresectable, locally advanced, or metastatic disease at the time of diagnosis. Moreover, traditional treatments such as chemotherapy, surgery, and radiation have not been shown to significantly improve survival. Recently, there has been a swift increase in cancer treatments that incorporate immunotherapy-based strategies to target all the stepwise events required for tumor initiation and progression. The results in melanoma, non-small-cell lung cancer and renal cell carcinoma are very encouraging. Unfortunately, the application of checkpoint inhibitors, including anti-CTLA4, anti-PD-1, and anti-PD-L1 antibodies, in pancreatic cancer has been disappointing. Many studies have revealed that the PDAC microenvironment supports tumor growth, promotes metastasis and consists of a physical barrier to drug delivery. Combination therapies hold great promise for enhancing immune responses to achieve a better therapeutic effect. In this review, we provide an outline of why pancreatic cancer is so lethal and of the treatment hurdles that exist. Particular emphasis is given to the role of the tumor microenvironment, and some of the latest and most promising studies on immunotherapy in PDAC are also presented.

 

Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches.

Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, Schnurr M, Lauber K. Radiat Oncol. 2019 Aug 8;14(1):141. doi: 10.1186/s13014-019-1345-6. PMID: 31395068; PMCID: PMC6688256.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with poor prognosis and rising incidence. Late detection and a particularly aggressive biology are the major challenges which determine therapeutic failure. In this review, we present the current status and the recent advances in PDAC treatment together with the biological and immunological hallmarks of this cancer entity. On this basis, we discuss new concepts combining distinct treatment modalities in order to improve therapeutic efficacy and clinical outcome – with a specific focus on protocols involving radio(chemo)therapeutic approaches.

 

Pancreatic ductal adenocarcinomas (PDACs), the most prevalent pancreatic cancer, is highly aggressive with a 5-year overall survival rate of less than 8%.  Late detection, it´s metastatic spread and the resistance to chemotherapy are among some of the factors responsible for poor patient outcome. The PDAC incidence rate is increasing and is particularly related to the general aging of our society. Furthermore, life stye habits that include abuse of alcohol and tobacco as well as obesity and type 2 diabetes increases the risk for various types of cancer including PDAC.